BRIEF-Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease Therapeutics

Reuters

Mar 05

BRIEF-Tenaya <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease Therapeutics

March 5 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:

TENAYA THERAPEUTICS ENTERS INTO RESEARCH COLLABORATION WITH ALNYLAM PHARMACEUTICALS TO IDENTIFY AND VALIDATE NOVEL GENETIC TARGETS FOR CARDIOVASCULAR DISEASE THERAPEUTICS
TENAYA THERAPEUTICS INC - TO RECEIVE UP TO $10 MILLION UPFRONT AND UP TO $1.13 BILLION IN MILESTONE PAYMENTS
TENAYA THERAPEUTICS INC - CO TO VALIDATE UP TO 15 GENE TARGETS UNDER AGREEMENT

Source text: ID:nGNX2WBv5H

Further company coverage: ALNY.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2617458540"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2617458540\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2617458540?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617458540","market":"nz","top_or_hot":-1,"title":"BRIEF-Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease Therapeutics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Tenaya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease Therapeutics</title></head><body><p><span>March 5 (Reuters)</span><span> - </span>Alnylam Pharmaceuticals Inc <span>ALNY.O</span>:</p><ul><li><p>TENAYA THERAPEUTICS ENTERS INTO RESEARCH COLLABORATION WITH ALNYLAM PHARMACEUTICALS TO IDENTIFY AND VALIDATE NOVEL GENETIC TARGETS FOR CARDIOVASCULAR DISEASE THERAPEUTICS</p></li><li><p>TENAYA THERAPEUTICS INC - TO RECEIVE UP TO $10 MILLION UPFRONT AND UP TO $1.13 BILLION IN MILESTONE PAYMENTS</p></li><li><p>TENAYA THERAPEUTICS INC - CO TO VALIDATE UP TO 15 GENE TARGETS UNDER AGREEMENT</p></li></ul><p>Source text: <span>ID:nGNX2WBv5H</span></p><p>Further company coverage: <span>ALNY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-05 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Tenaya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease Therapeutics</title></head><body><p><span>March 5 (Reuters)</span><span> - </span>Alnylam Pharmaceuticals Inc <span>ALNY.O</span>:</p><ul><li><p>TENAYA THERAPEUTICS ENTERS INTO RESEARCH COLLABORATION WITH ALNYLAM PHARMACEUTICALS TO IDENTIFY AND VALIDATE NOVEL GENETIC TARGETS FOR CARDIOVASCULAR DISEASE THERAPEUTICS</p></li><li><p>TENAYA THERAPEUTICS INC - TO RECEIVE UP TO $10 MILLION UPFRONT AND UP TO $1.13 BILLION IN MILESTONE PAYMENTS</p></li><li><p>TENAYA THERAPEUTICS INC - CO TO VALIDATE UP TO 15 GENE TARGETS UNDER AGREEMENT</p></li></ul><p>Source text: <span>ID:nGNX2WBv5H</span></p><p>Further company coverage: <span>ALNY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA7W8SVV:1","article_id":"2617458540","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617458540","pubTimestamp":1772717493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease TherapeuticsMarch 5 (Reuters) - Alny","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU0882574055.USD":"富达全球健康医疗A ACC","BK4585":"ETF&股票定投概念","BK4539":"次新股","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","ALNY":"阿尔尼拉姆制药公司","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4548":"巴美列捷福持仓","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","TNYA":"Tenaya Therapeutics Inc"},"translate_title":"简介-Tenaya Therapeutics与Alnylam Pharmaceuticals开展研究合作，以识别和验证心血管疾病治疗的新型基因靶点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNYA":0.9,"ALNY":0.9},"content_text":"BRIEF-Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease TherapeuticsMarch 5 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:TENAYA THERAPEUTICS ENTERS INTO RESEARCH COLLABORATION WITH ALNYLAM PHARMACEUTICALS TO IDENTIFY AND VALIDATE NOVEL GENETIC TARGETS FOR CARDIOVASCULAR DISEASE THERAPEUTICSTENAYA THERAPEUTICS INC - TO RECEIVE UP TO $10 MILLION UPFRONT AND UP TO $1.13 BILLION IN MILESTONE PAYMENTSTENAYA THERAPEUTICS INC - CO TO VALIDATE UP TO 15 GENE TARGETS UNDER AGREEMENTSource text: ID:nGNX2WBv5HFurther company coverage: ALNY.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}